Cormedix (STU:19KA) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 05, 2026)


STU:19KA Cormedix Inc STU:19KA
44 GF Score
Price €7.46
GF Value €56.45
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Cormedix Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Cormedix's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

STU:19KA vs STTK, ACHV, EIKN: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Cormedix's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cormedix Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cormedix's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Cormedix's Margin of Safety % (DCF Earnings Based) falls into.


STU:19KA
44GF Score
Cormedix Inc STU:19KA
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cormedix (STU:19KA) Overvalued in 2026?

Based on GuruFocus' analysis, Cormedix stock appears to be undervalued. The current stock price of €7.46 is trading 86.8% below its estimated GF Value™ of €56.45. GuruFocus considers Cormedix to be Possible Value Trap.

Key valuation signals for STU:19KA:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €56.45 vs. price of €7.46 (86.8% below fair value)
  • GF Score™: 44/100 with 6 warning signs

No single metric tells the full story. See the STU:19KA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cormedix Business Description

Other Exchanges CRMD:USA
Address 389 Interpace Parkway, Suite 450, Parsippany, NJ, USA, 07054
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
44GF Score

Get the complete analysis for STU:19KA

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.46
Price
€56.45
GF Value